JS107
/ Shanghai Junshi Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
October 04, 2025
Updated results from a phase I study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), in combination with toripalimab and chemotherapy as the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA)
(ESMO Asia 2025)
- P1 | "JS107 in combination with toripalimab and XELOX as the first-line treatment for CLDN18.2-high advanced G/GEJA showed encouraging efficacy with a manageable safety profile, warranting further evaluation in phase 3 trials."
Clinical • Combination therapy • Late-breaking abstract • Metastases • P1 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • CLDN18 • HER-2
June 06, 2025
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P1 | N=8 | Terminated | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | N=106 ➔ 8 | Not yet recruiting ➔ Terminated | Trial primary completion date: Sep 2024 ➔ Jan 2025; Company research and development strategy adjustment
Enrollment change • Trial primary completion date • Trial termination • Oncology • Pancreatic Cancer • Solid Tumor
March 26, 2025
Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors
(AACR 2025)
- P1 | "JS107 monotherapy or in combination with toripalimab and XELOX showed promising efficacy in pts with CLDN18.2-high advanced GC/GEJ with a manageable safety profile. The clinical benefit of CLDN18.2 ADC combination treatment was thus demonstrated for the first time. Further clinical development of JS107 in CLDN18.2+ advanced solid tumors is warranted."
Clinical • Metastases • Monotherapy • P1 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18 • HER-2
December 20, 2022
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P1 | N=106 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Metastases • New P1 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
August 16, 2022
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=118 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.
New P1 trial • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1